Enhanced LC–MS/MS analysis of alogliptin and pioglitazone in human plasma: Applied to a preliminary pharmacokinetic study

Farouk, Maha; Ayad, Miriam F.; Tadros, Mariam M.

doi:10.1016/j.jchromb.2017.04.043

Cited by 21 publications

(17 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The proposed repositioning study of OG, after the proof of crossing BBB, will be of interest for pharmaceutical industry & researchers working in the area of PD treatment with the major advantages of repositioning that include safety, saving time & money. Preliminary investigations confirmed that alogliptin is a suitable internal standard (IS) with similar physical and chemical properties while performing the simple sample extraction procedures 45 – 47 as shown in its structure presented in Fig. 1c .…”

Section: Introductionmentioning

confidence: 72%

Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent

Ayoub

Mowaka

Safar

et al. 2018

Sci Rep

Self Cite

View full text Add to dashboard Cite

Drug repositioning is a revolution breakthrough of drug discovery that presents outstanding privilege with already safer agents by scanning the existing candidates as therapeutic switching or repurposing for marketed drugs. Sitagliptin, vildagliptin, saxagliptin & linagliptin showed antioxidant and neurorestorative effects in previous studies linked to DPP-4 inhibition. Literature showed that gliptins did not cross the blood brain barrier (BBB) while omarigliptin was the first gliptin that crossed it successfully in the present work. LC-MS/MS determination of once-weekly anti-diabetic DPP-4 inhibitors; omarigliptin & trelagliptin in plasma and brain tissue was employed after 2 h of oral administration to rats. The brain/plasma concentration ratio was used to deduce the penetration power through the BBB. Results showed that only omarigliptin crossed the BBB due to its low molecular weight & lipophilic properties suggesting its repositioning as antiparkinsonian agent. The results of BBB crossing will be of interest for researchers interested in Parkinson’s disease. A novel intranasal formulation was developed using sodium lauryl sulphate surfactant to solubilize the lipophilic omarigliptin with penetration enhancing & antimicrobial properties. Intranasal administration showed enhanced brain/plasma ratio by 3.3 folds compared to the oral group accompanied with 2.6 folds increase in brain glucagon-like peptide-1 concentration compared to the control group.

show abstract

Section: Introductionmentioning

confidence: 72%

Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent

Ayoub

Mowaka

Safar

et al. 2018

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…The reported C max of alogliptin is 0.11 µg/mL at a dose of 25 mg [23]. Due to the low C max , determination of alogliptin in plasma necessitated using highly sensitive techniques such as LC-MS/MS after protein precipitation of samples [23][24][25][26]. However, protein precipitation induces ionization suppression in MS detection [27,28] and precludes detection by other less sensitive detectors such as UV.…”

Section: Introductionmentioning

confidence: 99%

Salting-Out Induced Liquid-Liquid Microextraction for Alogliptin Benzoate Determination in Human Plasma by HPLC/UV

Hammad

Abdallah

Bedair

et al. 2020

Preprint

View full text Add to dashboard Cite

Salting-out induced liquid-liquid microextraction method has been developed for plasma sample treatment before determination of alogliptin by high performance liquid chromatography with UV detection. Several parameters were optimized to achieve maximum enrichment including type of extractant, volume of extractant, type of anion, type of cation, salt amount and pH. The optimum conditions were achieved using 500 µL of acetonitrile, added to 1 mL of aqueous sample containing 250 mg of sodium chloride at pH 12. An RP-HPLC method was developed and validated according to the International Conference on Harmonization guidelines Q2 (R1). The method was linear in the concentration range of 0.1 to 50 µg/mL (correlation coefficient= 0.997). The limit of detection was 19 ng/mL and limit of quantitation was 60 ng /mL. The method was accurate and precise with a % recovery of 99.7% and a % relative standard deviation ranging between 1.5 and 2.5. These results showed that the salting-out induced liquid-liquid microextraction methods could be better than other sample preparation protocols in terms of sensitivity, easiness, solvent consumption and waste reduction.

show abstract

“…Only one chromatographic method reported ALO estimation in biofluid with a quantitation limit of 1.983 μg.ml −1 . However, this concentration is, so far, more than the C max of ALO, 100.50 ng ml −1 . Only liquid chromatography–mass spectrometry (LC–MS) techniques were capable of measuring the ALO level in rat, monkey, as well as in human .…”

Section: Introductionmentioning

confidence: 99%

“…However, this concentration is, so far, more than the C max of ALO, 100.50 ng ml −1 . Only liquid chromatography–mass spectrometry (LC–MS) techniques were capable of measuring the ALO level in rat, monkey, as well as in human . However, their expensive sophisticated instrumentation, longer duration of analysis, lengthy procedures for sample clean‐up, and increased cost for analysis preclude their application in some bioanalytical laboratories especially in the less developed countries.…”

Section: Introductionmentioning

confidence: 99%

“…[6] Only liquid chromatography-mass spectrometry (LC-MS) techniques were capable of measuring the ALO level in rat [7] , monkey [8] , as well as in human. [6] However, their expensive sophisticated instrumentation, longer duration of analysis, lengthy procedures for sample clean-up, and increased cost for analysis preclude their application in some bioanalytical laboratories especially in the less developed countries. Although, the application of fluorescence for the determination of trace concentration of biologically active drugs has significantly increased, as it is simple, highly sensitive,…”

mentioning

confidence: 99%

See 1 more Smart Citation

Novel spectrofluorimetric quantification of alogliptin benzoate in biofluids exploiting its interaction with 4‐chloro‐7‐nitrobenzofurazan

Aref¹,

Hammad

Darwish

et al. 2019

Luminescence

View full text Add to dashboard Cite

The direct determination of alogliptin benzoate (ALO) using fluorescence has not yet been accomplished because ALO cannot fluoresce naturally. Accordingly, it should be derivatized first with a fluorogenic reagent to enhance the sensitivity required for its bioanalysis. This method is the first spectrofluorimetric assay for ALO quantification exploiting the nucleophilic nature of its amino group to react with 4‐chloro‐7‐nitrobenzofurazan (NBD‐Cl) in borate buffer at pH 8.5 to produce a strong fluorescent compound that is excited at and emits at wavelengths 470 and 527 nm, respectively. Experimental variables concerning the conditions of reaction and fluorogenic intensity were carefully investigated and optimized. Linearity was from 1–250 ng ml−1 with a lower detection limit of 0.29 ng ml−1 and a lower quantification limit of 0.88 ng ml−1. Validation of the current study was accomplished with mean per cent recovery of 100.62 ± 1.59 in tablets and 99.86 ± 0.82 in human plasma. Furthermore, the current method has been utilized in the bioanalysis of ALO in real rat plasma after oral administration with a simple specimen preparation. The developed method has proven to be a promising alternative method for ALO analysis in bioequivalence studies.

show abstract

Enhanced LC–MS/MS analysis of alogliptin and pioglitazone in human plasma: Applied to a preliminary pharmacokinetic study

Cited by 21 publications

References 25 publications

Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent

Repositioning of Omarigliptin as a once-weekly intranasal Anti-parkinsonian Agent

Salting-Out Induced Liquid-Liquid Microextraction for Alogliptin Benzoate Determination in Human Plasma by HPLC/UV

Novel spectrofluorimetric quantification of alogliptin benzoate in biofluids exploiting its interaction with 4‐chloro‐7‐nitrobenzofurazan

Contact Info

Product

Resources

About